Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 24, Number 4—April 2018
Research

Carbapenem-Nonsusceptible Acinetobacter baumannii, 8 US Metropolitan Areas, 2012–2015

Sandra N. BulensComments to Author , Sarah H. Yi, Maroya S. Walters, Jesse T. Jacob, Chris Bower, Jessica Reno, Lucy Wilson, Elisabeth Vaeth, Wendy Bamberg, Sarah J. Janelle, Ruth Lynfield, Paula Snippes Vagnone, Kristin Shaw, Marion Kainer, Daniel Muleta, Jacqueline Mounsey, Ghinwa Dumyati, Cathleen Concannon, Zintars Beldavs, P. Maureen Cassidy, Erin C. Phipps, Nicole Kenslow, Emily B. Hancock, and Alexander J. Kallen
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.N. Bulens, S.H. Yi, M.S. Walters, A.J. Kallen); Emory University School of Medicine, Atlanta (J.T. Jacob); Georgia Emerging Infections Program, Atlanta (J.T. Jacob, C. Bower, J. Reno); Atlanta Veterans Affairs Medical Center, Decatur, Georgia, USA (C. Bower, J. Reno); Atlanta Research and Education Foundation, Decatur (C. Bower, J. Reno); Maryland Department of Health and Mental Hygiene, Baltimore, Maryland, USA (L. Wilson, E. Vaeth); Colorado Department of Public Health and Environment, Denver, Colorado, USA (W. Bamberg, S.J. Janelle); Minnesota Department of Health, St. Paul, Minnesota, USA (R. Lynfield, P.S. Vagnone, K. Shaw); Tennessee Department of Public Health, Nashville, Tennessee, USA (M. Kainer, D. Muleta, J. Mounsey); New York Rochester Emerging Infections Program at the University of Rochester Medical Center, Rochester, New York, USA (G. Dumyati, C. Concannon); Oregon Health Authority, Portland, Oregon, USA (Z. Beldavs, P.M. Cassidy); University of New Mexico, Albuquerque, New Mexico, USA (E.C. Phipps, N. Kenslow, E.B. Hancock)

Main Article

Table 3

Outcomes for 598 Acinetobacter baumannii cases in Emerging Infections Program sites, United States, 2012–2015*

Outcome No. (%)
Hospitalized at, or within 30 d after, date of specimen collection, n = 598 449 (75.1)
Admission to intensive care unit on day of or within 7 d after sample collection, n = 449 168 (37.4)
Discharge location after acute care hospitalization among patients who survived, n = 356†
Long-term care facility 187 (52.5))
Private residence 131 (36.8)
Long-term acute care hospital 34 (9.6))
Other
 1 (0.3)
Died,‡ n = 594 106 (17.9)
Among cases with a sterile site culture, n = 172§ 71 (41.3)
Among cases with a positive urine culture, n = 422§ 35 (8.3)

*The study areas were Denver, Colorado; Atlanta, Georgia; Baltimore, Maryland; Minneapolis/Saint Paul, Minnesota, Albuquerque, New Mexico; Rochester, New York; Portland, Oregon; Nashville, Tennessee.
†Three case-patients were discharged to unknown locations.
‡Death was determined at discharge for hospital inpatients; 30 d after sample collection for case-patients identified in outpatient dialysis, long-term care, and long-term acute care hospitals; and at evaluation for outpatients. For 4 case-patients, outcome was unknown. The 1 patient who had a blood sampel and a urine was counted in the “sterile site culture” category.
§Significant difference in death by specimen source (p<0.0001).

Main Article

Page created: March 19, 2018
Page updated: March 19, 2018
Page reviewed: March 19, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external